These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. [Dispensary observation of patients with urinary bladder tumors (according to materials from the N. N. Petrov Research Institute of Oncology of the MH of the USSR)]. Berman NA; Mirotvortseva KS Vopr Onkol; 1972; 18(6):71-5. PubMed ID: 5042744 [No Abstract] [Full Text] [Related]
3. [What place can chemotherapy occupy in the treatment of infiltrating transitional carcinoma of the bladder?]. Escudero Barrilero A; Jiménez Cidre M; Gutiérrez Sanz-Gadea C; Mateos Torres A; Maganto Pavón E; Mayayo Dehesa T; Allona Almagro A Arch Esp Urol; 1986; 39(9):617-27. PubMed ID: 3827327 [No Abstract] [Full Text] [Related]
4. Bladder carcinoma treated by irradiation and surgery: interval report. Deweerd JH; Colby MY Trans Am Assoc Genitourin Surg; 1972; 64():74-8. PubMed ID: 4654525 [No Abstract] [Full Text] [Related]
5. [Synchronous double cancer of the esophagus and the urinary bladder: report of two cases]. Takai K; Moriyama N; Shinohara M; Fukutani K; Mikata N; Yokoyama M; Kogure T Hinyokika Kiyo; 1983 Sep; 29(9):1085-9. PubMed ID: 6677142 [TBL] [Abstract][Full Text] [Related]
6. Prognostic factors for primary superficial transitional cell carcinoma of the bladder: a retrospective cohort study. Yang TB; Zeng FH; Sun ZQ Chin Med J (Engl); 2006 Nov; 119(21):1821-8. PubMed ID: 17097038 [TBL] [Abstract][Full Text] [Related]
7. [Advances in the treatment of infiltrating transitional cancer of the bladder]. Escudero Barrilero A Arch Esp Urol; 1996 May; 49(4):317-23; discussion 323-35. PubMed ID: 8754189 [No Abstract] [Full Text] [Related]
8. New generation of prognostic factors in muscle invasive bladder cancer. Abi-Aad AS Acta Urol Belg; 1996 May; 64(2):47-9. PubMed ID: 8701811 [No Abstract] [Full Text] [Related]
10. [Bladder cancer in elderly patients]. Isaka S; Igarashi T; Akimoto S; Okano T; Shimazaki J; Matsuzaki O Hinyokika Kiyo; 1984 Dec; 30(12):1793-9. PubMed ID: 6532207 [TBL] [Abstract][Full Text] [Related]
11. Evaluation criteria: a protocol to study patterns of care and their effects in patients with transitional cell carcinoma of the bladder (protocol 1). Prout GR; Kopp J Prog Clin Biol Res; 1984; 162A():285-99. PubMed ID: 6483913 [No Abstract] [Full Text] [Related]
12. Bilharzial related, organ confined, muscle invasive bladder cancer: prognostic value of apoptosis markers, proliferation markers, p53, E-cadherin, epidermal growth factor receptor and c-erbB-2. Haitel A; Posch B; El-Baz M; Mokhtar AA; Susani M; Ghoneim MA; Marberger M J Urol; 2001 May; 165(5):1481-7. PubMed ID: 11342901 [TBL] [Abstract][Full Text] [Related]
13. [Consideration of therapeutic choice for grade 3 superficial bladder cancer]. Noguchi S; Kubota Y; Takase K; Masuda M; Yao M; Hosaka M; Miura T; Kondoh I; Kawasaki C; Moriyama M Hinyokika Kiyo; 1996 Sep; 42(9):635-8. PubMed ID: 8918660 [TBL] [Abstract][Full Text] [Related]
14. [Superficial bladder cancer. Open questions]. Böhle A Urologe A; 1994 Nov; 33(6):536-9. PubMed ID: 7817453 [TBL] [Abstract][Full Text] [Related]
15. Interleukin-2 in the treatment of infiltrating bladder cancer. Pizza G; Berton F; Casanova S; De Vinci C; Corrado F J Exp Pathol; 1987; 3(4):525-31. PubMed ID: 3502649 [No Abstract] [Full Text] [Related]
16. [Treatment of muscle-infiltrating bladder cancer (P2/P3) with partial cystectomy]. Fosså SD; Kaalhus O; Gjersvik T; Segadal E Tidsskr Nor Laegeforen; 1982 Apr; 102(11):627-9. PubMed ID: 7157240 [No Abstract] [Full Text] [Related]